# Duvelisib in Hepatically Impaired Subjects Compared to Healthy Subjects

> **NCT02095587** · PHASE1 · COMPLETED · sponsor: **SecuraBio** · enrollment: 24 (actual)

## Conditions studied

- Hepatic Impairment

## Interventions

- **DRUG:** IPI-145

## Key facts

- **NCT ID:** NCT02095587
- **Lead sponsor:** SecuraBio
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03
- **Primary completion:** 2014-07
- **Final completion:** 2014-10
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2021-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02095587

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02095587, "Duvelisib in Hepatically Impaired Subjects Compared to Healthy Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02095587. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*